



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/739,940	09/739,940 12/19/2000		Stephen J. Fonash	30626-101	30626-101 4788	
26486	7590	03/11/2004		EXAM	EXAMINER	
PERKINS, ONE BEACO		& COHEN LLP	TRAN, MY	TRAN, MY CHAU T		
	30TH FLOOR			ART UNIT	PAPER NUMBER	
BOSTON, N	1A 0210	8		1639		

DATE MAILED: 03/11/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
		09/739,940	FONASH ET AL.
	Office Action Summary	Examiner	Art Unit
		MY-CHAU T TRAN	1639
Period fo	The MAILING DATE of this communication or Reply	appears on the cover sheet with the	ne correspondence address
A SH THE - Exte after - If the - If NC - Failu Any	CORTENED STATUTORY PERIOD FOR REMAILING DATE OF THIS COMMUNICATIOnsions of time may be available under the provisions of 37 CFI SIX (6) MONTHS from the mailing date of this communication as period for reply specified above is less than thirty (30) days, as period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	ON. R 1.136(a). In no event, however, may a reply b a reply within the statutory minimum of thirty (30) riod will apply and will expire SIX (6) MONTHS to atute, cause the application to become ABANDO	be timely filed days will be considered timely. from the mailing date of this communication. ONED (35 U.S.C. § 133).
Status			
•	Responsive to communication(s) filed on <u>0</u> This action is FINAL . 2b) 1 Since this application is in condition for allo closed in accordance with the practice under	This action is non-final. wance except for formal matters,	
Disposit	ion of Claims		
5)	Claim(s) <u>1-3,6,7,10-12,14-19,66,67,69,70 a</u> 4a) Of the above claim(s) <u>119-124</u> is/are wire Claim(s) is/are allowed. Claim(s) <u>1-3,6,7,10-12,14-19,66,67,69,70 a</u> Claim(s) is/are objected to. Claim(s) are subject to restriction and	thdrawn from consideration. and 125 is/are rejected.	application.
Applicati	ion Papers		
10)⊠	The specification is objected to by the Exame The drawing(s) filed on <u>22 July 2002</u> is/are: Applicant may not request that any objection to Replacement drawing sheet(s) including the core The oath or declaration is objected to by the	a)⊠ accepted or b)⊡ objected t the drawing(s) be held in abeyance. rection is required if the drawing(s) is	See 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).
Priority ι	ınder 35 U.S.C. § 119		
a)l	Acknowledgment is made of a claim for fore All b) Some * c) None of: 1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the papplication from the International Bur See the attached detailed Office action for a	ents have been received. ents have been received in Applic priority documents have been rece reau (PCT Rule 17.2(a)).	cation No eived in this National Stage
A44 1-	M-3		
	e of References Cited (PTO-892)	4) 🔲 Interview Summ	ary (PTO-413)
2)	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB, r No(s)/Mail Date	Paper No(s)/Mai	

Art Unit: 1639

DETAILED ACTION

1. The Examiner regrets any inconvenience to Applicant caused by the telephonic interview of 2/27/04 wherein the examiner has indicated the allowance of claims 1-3, 6-7, 10-12, 14-19, 66-67, 69-70, and 125. However on review of the amended claim 1 and search for the new limitations, a new reference was found.

Status of Claims

- 2. Applicant's amendment filed 12/3/03 is acknowledged and entered. Claims 1, 6-7, 10-11, 17, 66-67, and 69-70 have been amended. Claim 125 has been added. It is noted that applicant has improperly stated the status of claims 22-65 as "withdrawn" when they were canceled by the amendment filed 11/25/02 and 12/2/02.
- 3. In the amendment filed on 7/22/02, Claims 4, 5, 8, and 13 have been canceled and Claims 66-118 have been added.
- 4. Claims 9, 20-65, 68, and 71-118 have been canceled by the amendment filed on 11/25/02 and 12/2/02.
- 5. In the amendment filed on 6/9/03, applicant has indicated that the status of claims 22-65 as being withdrawn when the amendment filed 11/25/02 and 12/2/02 has canceled claims 22-65. Therefore, Claims 22-65 are considered canceled.

Art Unit: 1639

6. In the amendment filed on 6/24/03, Claims 119-125 have been added and improperly stated the status of claims 22-65 as "withdrawn" when they were canceled by the amendment filed 11/25/02 and 12/2/02.

- 7. Claims 1-3, 6-7, 10-12, 14-19, 66-67, 69-70, and 119-125 are pending.
- 8. Claims 119-124 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Withdrawn Objections and /or Rejections

- 9. The previous rejection under 35 USC 112, first paragraph (new matter) of claims 1-3, 6-7, 10-12, 14-19, 66-67, and 69-70 has been withdrawn in view of the amendment of claims 1, 6-7, 10-11, 17, 66-67, and 69-70.
- 10. The rejections under 35 USC 112, second paragraph of claims 1-3, 6-7, 10-12, 14-19, 66-67, 69-70 has been withdrawn in view of the amendment of claims 1, 6-7, 10-11, 17, 66-67, and 69-70.
- 11. The rejection under 35 USC 102(b) as being anticipated by Hutchens et al. (US Patent 5,719,060) for claims 1-2, 10, 12, 14, and 69-70 has been withdrawn in view of the amendment of claim 1.

Page 4

Application/Control Number: 09/739,940

Art Unit: 1639

- 12. The rejection under 35 USC 102(e) as being anticipated by Nelson et al. (US Patent 5,955,729) for claims 1-3, 10, 12, 14, 17, 66, and 69-70 has been withdrawn in view of the amendment of claim 1.
- 13. The rejection under 35 USC 102(e) as being anticipated by Siuzdak et al. (US Patent 6,288,390) for claims 1-2, 6-7, 10-12, 14, 17, 66, and 69-70 has been withdrawn in view of the amendment of claim 1.
- 14. The rejection under 35 USC 103(a) as being unpatentable over Siuzdak et al. (US Patent 6,288,390) in view of Mian et al. (US Patent 6,319,469) for claims 1-2, 6-7, 10-12, 14, 17-19, 66-67, and 69-70 has been withdrawn in view of the amendment of claim 1.
- 15. The rejection under 35 USC 103(a) as being unpatentable over Siuzdak et al. (US Patent 6,288,390) in view of Farmer et al. (*J. Mass Spectrom.*, **1998**, 3:697-704) for claims 1, and 15-16 has been withdrawn in view of the amendment of claim 1.
- 16. Claims 1-3, 6-7, 10-12, 14-19, 66-67, 69-70, and 125 are treated on the merit in this Office Action.

Claim Rejections - 35 USC § 102

17. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 1639

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

18. Claims 1-3, 6-7, 10, 12, 14, 17-19, 66-67, 69-70, and 125 are rejected under 35 U.S.C. 102(b) as being anticipated by Bal et al. (*Anal. Chem.*, **1994**, 66:3423-3430).

Bal et al. disclose a method of analyzing protein by matrix-assisted laser desorption/ionization mass spectrometry (MALDI mass spectrometry) (Abstract; pg. 3423, left col., lines 1-6; pg. 3424, left col., line 45 to right col., line 17). The method comprises depositing a nafion film by evaporation onto a stainless-steel probe (metal substrate) (pg. 3425, lines 13-27) and applying the sample directly onto the nafion film after the deposition of the film (pg. 3425, left col., line 39 to right col., line 2). The nafion film is a perfluorinated cation exchanger with sulfonic acid groups (carbon hydrogen mixture) and possesses a high surface activity and can selectively bind small cations and organic cations covalently (species adsorption/analyte adsorption) (pg. 3424, left col., line 45 to right col., line 17). The protein sample is obtained by electrophoretic analysis and HPLC (pg. 3424, right col., line 50 to pg. 3425, left col., line 12; pg. 3425, lines 30-39). The sample is mix with a matrix (chemically modifying the film) (pg. 3424, right col., lines 37-49). The sample is analyzed by laser mass spectrometry (pg. 3424, right col., line 20-36).

Claim Rejections - 35 USC § 103

- 19. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are

Art Unit: 1639

such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

20. Claims 1-3, 6-7, 10-12, 14-19, 66-67, 69-70, and 125 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bal et al. (*Anal. Chem.*, **1994**, 66:3423-3430) and Farmer et al. (*J. Mass Spectrom.*, **1998**, 33:697-704).

Bal et al. disclose a method of analyzing protein by matrix-assisted laser desorption/ionization mass spectrometry (MALDI mass spectrometry) (Abstract; pg. 3423, left col., lines 1-6; pg. 3424, left col., line 45 to right col., line 17). The method comprises depositing a nafion film by evaporation onto a stainless-steel probe (metal substrate) (pg. 3425, lines 13-27) and applying the sample directly onto the nafion film after the deposition of the film (pg. 3425, left col., line 39 to right col., line 2). The nafion film is a perfluorinated cation exchanger with sulfonic acid groups (carbon hydrogen mixture) and possesses a high surface activity and can selectively bind small cations and organic cations covalently (species adsorption/analyte adsorption) (pg. 3424, left col., line 45 to right col., line 17). The protein sample is obtained by electrophoretic analysis and HPLC (pg. 3424, right col., line 50 to pg. 3425, left col., line 12; pg. 3425, lines 30-39). The sample is mix with a matrix (chemically modifying the film) (pg. 3424, right col., lines 37-49). The sample is analyzed by laser mass spectrometry (pg. 3424, right col., line 20-36).

The method of Bal et al. does not expressly disclose enhancing the signal by using ammonium citrate as a signal enhancer.

Farmer et al. teach a method of studying protein-protein and protein-ligand interactions by mass spectrometry (pg. 697, left col. 17-19). The mass spectrometry technique is matrix-assisted laser desorption/ionization mass spectrometry (MALDI mass spectrometry). The

Art Unit: 1639

method comprises dissolving both the matrix and the analytes in ammonium citrate (pg. 700, right col., lines 19-41), which provided an intense signal (pg. 700, right col., lines 42-51).

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to include ammonium citrate as a signal enhancer as taught by Farmer et al. in the method of Bal et al. One of ordinary skill in the art would have been motivated to include ammonium citrate as a signal enhancer in the method of Bal et al. for the advantage of providing a reagent that sequesters ions such as salt that is generally found in bimolecular analysis because the salt would form adduct peaks in a mass spectrum that compete with the peaks of the molecular ion dividing and broadening the overall signal since both Bal et al. and Farmer et al. disclose the method of analyzing protein by matrix-assisted laser desorption/ionization mass spectrometry (Bal: Abstract; Farmer: Abstract). Furthermore, one of ordinary skill in the art would have reasonably expectation of success in the method combination of Bal et al. and Farmer et al. because pH of the sample is an important factor in the detection of non-covalent complexes and changing conditions of pH and ionic strength due to solvent evaporation will affect the complex stability by disrupting inter- and intramolecular forces.

Conclusion

21. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

Art Unit: 1639

MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MY-CHAU T TRAN whose telephone number is 571-272-0810. The examiner can normally be reached on Mon.: 8:00-2:30; Tues.-Thurs.: 7:30-5:00; Fri.: 8:00-3:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, ANDREW WANG can be reached on 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

mct March 8, 2004

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600